Principles of chemotherapy.

  title={Principles of chemotherapy.},
  author={Josephine A McKnight},
  journal={Clinical techniques in small animal practice},
  volume={18 2},
  • J. A. McKnight
  • Published 1 May 2003
  • Medicine
  • Clinical techniques in small animal practice
Chemotherapeutic agents can be used to increase both the length and the quality of the lives of patients with a wide variety of neoplastic diseases. The therapeutic index for many of these agents is very narrow; thus, close attention must be paid to proper dosing and timing of treatment. Proper patient selection is also critical for successful chemotherapy treatment. If the clinician is familiar with the agents being used, then toxicities can often be anticipated and then treated, or in some… 

Figures from this paper

Principles of Chemotherapy in Hodgkin Lymphoma

Hodgkin lymphoma was perhaps the disease for which the possibility of cure with combination chemotherapy in the majority of patients was first realized, and it is interesting to follow the trajectory of knowledge from early single-agent work through combinations, combined modalities, increasing complexity, and most recently, selective de-escalation.

Chemotherapy and Novel Cancer Targeted Therapies

During the past 10 years, initiatives have been undertaken by paediatric oncologists to further promote the clinical evaluation of new anti cancer compounds in children within national academic paediatric groups through proper evaluation in collaborative clinical trials.

Preclinical Screening for New Anticancer Agents

The aim of screening efforts is to identify products that will produce antitumor effects matching the activity criteria used to define which compounds can progress to the next stage in the preclinical development program.

Toxicities Associated with Antibody Drug Conjugates

This review focuses on various toxicities associated with the use of antibody-drug conjugates, a promising approach to enhance the efficacy of unconjugated antibodies for improved therapeutics and decreased toxicities.

Biological advances for new treatment approaches.

Pharmacologic modulation strategies to reduce dose requirements of anticancer therapy while preserving clinical efficacy.

This review will discuss pharmacologic modulation strategies that have been tested clinically in order to increase systemic drug exposure and important examples include ketoconazole inhibition of hepatic CYP3A4 in orderto increase systemic exposure to docetaxel, irinotecan and etoposide.

Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma.

Thirty-five dogs with appendicular osteosarcoma underwent amputation and chemotherapy with cisplatin and doxorubicin every 21 days for up to four cycles, with median survival time of 300 days not improved over previously reported single-agent protocols.

Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis

It is found that gemcitabine could significantly antagonize the cytotoxic effects of paclitaxel when tumor cells were exposed to the two drugs simultaneously or exposed to gem citabine before pac litaxel, however, there was little antagonistic interaction observed when pac Litaxel was administered before gemcitABine.



Chemotherapy and the surgery patient: principles and recent advances.

  • G. Ogilvie
  • Medicine, Biology
    Clinical techniques in small animal practice
  • 1998

Adjuvant chemotherapy for sarcomas and carcinomas.

  • A. HammerC. Couto
  • Medicine
    The Veterinary clinics of North America. Small animal practice
  • 1990

A comparison of doxorubicin and COP for maintenance of remission in cats with lymphoma.

Doxorubicin should be considered a well-tolerated and efficacious agent for the maintenance of remission in cats with lymphoma.

Hepatotoxicity associated with methotrexate therapy in a dog

A nine-year-old male Newfoundland-cross treated with doxorubicin, cyclophosphamide, and methotrexate as adjuvant chemotherapy following the resection of a maxillary osteosarcoma became anorexic, and developed icterus and ascites.

Chemotherapy of canine hemangiosarcoma with doxorubicin and cyclophosphamide.

Chemotherapy with doxorubicin and cyclophosphamide appears to improve survival with acceptable morbidity in patients with early stage disease in dogs with a histologic diagnosis of hemangiosarcoma.

Lomustine (CCNU) for the treatment of resistant lymphoma in dogs.

Cumulative thrombocytopenia occurred in dogs receiving continued CCNU treatment, and a dose interval of 3 weeks may be too short for continued administration of this drug.

Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin.

Dogs treated with asparaginase had a faster response to chemotherapy, a longer remission, and a longer survival time, compared with all dogs treated s.c.m. treatment.

Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors.

The most common signs of toxicosis after treatment with mitoxantrone were vomiting, anorexia, diarrhea, lethargy, sepsis secondary to myelosuppression, and seizures.

Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma.

It is indicated that systemic (adjuvant) chemotherapy delays relapse and may provide defiency to patients with osteogenic sarcoma with follow-up periods of two to 23 months.

Phase II evaluation of doxorubicin for treatment of various canine neoplasms.

One hundred eighty-five dogs with histologically confirmed, measurable malignant tumors were used in a prospective study to determine the response to 2 doses of the anthracycline antitumor